Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches (review)

Oncology Letters

Volumn 12, Issue 4, 2016, Pages 2283-2288

  Huang, Wen Juan ^a   Chen, Wei Wei ^a   Zhang, Xia ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Astrocytoma; Cancer stem cells; Glioblastoma; Hypoxia; Hypoxia inducible factor 1 ; Pseudopalisading necrosis; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVOFOSFAMIDE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PALIFOSFAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STEM CELL; CLINICAL TRIAL (TOPIC); DRUG TARGETING; GLIOBLASTOMA; HYPOXIA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 84983407936     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4952     Document Type: Review

References (57)

1. Filippini G: Epidemiology of primary central nervous system tumors. Handb Clin Neurol 104: 3-22, 2012.
2. Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z, et al (eds): Seer cancer statistics review, 1975-2013. National Cancer Institute, Bethesda, MD. http://seer.Cancer.Gov/csr/1975_2013/. Accessed April 15, 2016.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
4. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al: Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710, 2007.
5. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C and Barnholtz-Sloan J: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncol 16 (Suppl 4): iv1-iv63, 2014.
6. Hou LC, Veeravagu A, Hsu AR and Tse VC: Recurrent glioblastoma multiforme: A review of natural history and management options. Neurosurg Focus 20: E5, 2006.
7. Rong Y, Durden DL, Van Meir EG and Brat DJ: ‘Pseudopalisading’ necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65: 529-539, 2006.
8. Hsieh CH, Shyu WC, Chiang CY, Kuo JW, Shen WC and Liu RS: NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiforme. PLoS One 6: e23945, 2011.
9. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
10. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006.
11. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B and Van Meir EG: Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64: 920-927, 2004.
12. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG and Batchelor TT: Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622, 2007.
13. Jain RK: Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J Clin Oncol 31: 2205-2218, 2013.
14. Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, Adamsen TC, Link JM, Swanson PE, Yagle KJ, et al: Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: Correlation with time to progression and survival. Clin Cancer Res 14: 2623-2630, 2008.
15. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE II, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ and Rich JN: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26: 271-278, 2008.
16. Mannino M and Chalmers AJ: Radioresistance of glioma stem cells: Intrinsic characteristic or property of the ‘microenvironment-stem cell unit’? Mol Oncol 5: 374-386, 2011.
17. Plate KH, Breier G, Weich HA and Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992.
18. Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371, 2006.
19. Dimberg A: The glioblastoma vasculature as a target for cancer therapy. Biochem Soc Trans 42: 1647-1652, 2014.
20. Karpel-Massler G, Schmidt U, Unterberg A and Halatsch ME: Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: Where do we stand? Mol Cancer Res 7: 1000-1012, 2009.
21. Squatrito M and Holland EC: DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res 71: 5945-5949, 2011.
22. Riddick G and Fine HA: Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol 7: 439-450, 2011.
23. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W and Collins VP: Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 149: 29-35, 1996.
24. Massagué J: TGFbeta in Cancer. Cell 134: 215-230, 2008.
25. Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, et al: High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11: 147-160, 2007.
26. Dieterich LC, Mellberg S, Langenkamp E, Zhang L, Zieba A, Salomäki H, Teichert M, Huang H, Edqvist PH, Kraus T, et al: Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization. J Pathol 228: 378-390, 2012.
27. Shih AH and Holland EC: Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 232: 139-147, 2006.
28. Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee WK and Cheng SY: Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162: 1083-1093, 2003.
29. Lindblom P, Gerhardt H, Liebner S, Abramsson A, Enge M, Hellstrom M, Backstrom G, Fredriksson S, Landegren U, Nystrom HC, et al: Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 17: 1835-1840, 2003.
30. Kanu OO, Mehta A, Di C, Lin N, Bortoff K, Bigner DD, Yan H and Adamson DC: Glioblastoma multiforme: A review of therapeutic targets. Expert Opin Ther Targets 13: 701-718, 2009.
31. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, et al: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468: 824-828, 2010.
32. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S, et al: Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 108: 4274-4280, 2011.
33. Wolburg H, Noell S, Fallier-Becker P, Mack AF and Wolburg-Buchholz K: The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med 33: 579-589, 2012.
34. Gmeiner M, Sonnberger M, Wurm G and Weis S: Glioblastoma with the appearance of arteriovenous malformation: Pitfalls in diagnosis. Clin Neurol Neurosurg 115: 501-506, 2013.
35. Würth R, Bajetto A, Harrison JK, Barbieri F and Florio T: CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci 8: 144, 2014.
36. Blazek ER, Foutch JL and Maki G: Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133-cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 67: 1-5, 2007.
37. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402, 2007.
38. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et al: A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82, 2007.
39. Platet N, Liu SY, Atifi ME, Oliver L, Vallette FM, Berger F and Wion D: Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 258: 286-290, 2007.
40. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al: Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15: 501-513, 2009.
41. Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, Sloan AE, Iliopoulos O, Hjelmeland AB and Rich JN: Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ 19: 428-439, 2012.
42. Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W and Heimberger AB: Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 6: e16195, 2011.
43. Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L and Pieper RO: Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg 106: 417-427, 2007.
44. Lino MM, Merlo A and Boulay JL: Notch signaling in glioblastoma: A developmental drug target? BMC Med 8: 72, 2010.
45. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN and Sullenger BA: Notch promotes radioresistance of glioma stem cells. Stem Cells 28: 17-28, 2010.
46. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, et al: NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28: 5-16, 2010.
47. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, Xu W, Cui C, Xing Y, Liu Y, Cao B, Liu C, Wu G, Ao H, Zhang X and Jiang: Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci USA 110: 6829-6834, 2013.
48. Morgenroth A, Vogg AT, Ermert K, Zlatopolskiy B and Mottaghy FM: Hedgehog signaling sensitizes glioma stem cells to endogenous nano-irradiation. Oncotarget 5: 5483-5493, 2014.
49. Liu M, Inoue K, Leng T, Guo S and Xiong ZG: TRPM7 channels regulate glioma stem cell through STAT3 and Notch signaling pathways. Cell Signal 26: 2773-2781, 2014.
50. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, et al: Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108: 3749-3754, 2011.
51. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, et al: Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72: 402-407, 2012.
52. Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, et al: Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 11: 740-751, 2012.
53. Cavazos DA and Brenner AJ: Hypoxia in astrocytic tumors and implications for therapy. Neurobiol Dis 85: 227-233, 2016.
54. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
55. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
56. Yeo EJ, Ryu JH, Cho YS, Chun YS, Huang LE, Kim MS and Park JW: Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 107: 916-923, 2006.
57. Kirkpatrick J, Desjardins A, Quinn J, Rich J, Vredenburgh J, Sathornsumetee S, Gururangan S, Sidor C, Friedman H, Reardon D: Phase ii open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme. J Clin Oncol (ASCO Annual Meeting abs) 25: 2065, 2007